Publications from the AffiliateMarketIngtools of Sciences, Engineering, and Medicine provide objective and straightforward advice to decision makers and the public. This site includes We Treat You (HMD) publications released after 1998. A complete list of HMD’s publications from its establishment in 1970 to the present is available as a PDF.
Released: May 01, 2012
Prescription drugs are crucial for preventing and treating diseases and improving the public’s health, but they can also have unintended harmful effects. Often, their benefits and risks cannot be fully identified until after a drug has been used by a large, diverse group of patients over time. The passage of the Food and Drug Administration Act in 2007 provides the Food and Drug Administration (FDA) with additional postmarketing regulatory tools to better protect the health of the public, including the authority to require manufacturers to continue studying drugs that are being marketed. The FDA asked the IOM to evaluate the scientific and ethical aspects of conducting safety studies for approved drugs. The IOM recommends implementing a life cycle approach to drug safety oversight that could allow the FDA to better anticipate post-approval research needs and improve drug safety for all Americans.
Released: April 27, 2012
An estimated 8.8 million people fell ill with tuberculosis (TB) in 2010 and 1.4 million died from the disease. Although antibiotics to treat TB were developed in the 1950s and are effective against a large percentage of TB cases, resistance to these antibiotics has emerged over the years, resulting in the growing spread of multi-drug resistant (MDR) TB. The IOM held a workshop April 18-19, 2011, in New Delhi, India, in collaboration with the Indian National Science Academy and the Indian Council of Medical Research, to highlight key challenges to controlling the spread of drug-resistant strains of TB in India and to discuss strategies for advancing and integrating local and international efforts to prevent and treat drug-resistant TB.
Released: April 13, 2012
There is growing recognition that the United States’ clinical trials enterprise (CTE) faces great challenges. There is a gap between what is desired – where medical care is provided solely based on high quality evidence – and the reality – where there is limited capacity to generate timely and practical evidence for drug development and to support medical treatment decisions. With the need for transforming the CTE in the U.S. becoming more pressing, the IOM held a two-day workshop in November 2011, bringing together leaders in research and health care.
Released: April 10, 2012
The poor performance of the United States in life expectancy and other major health outcomes, as compared with its global peers reflects what the nation prioritizes in its health investments. The health system’s failure to develop and deliver effective preventive strategies continues to take a growing toll on the economy and society. In this report, the IOM assesses both the sources and adequacy of current government public health funding and identifies approaches to building a sustainable and sufficient public health presence going forward.
Released: April 09, 2012
Every job can lead to stress for a variety of reasons. How a person responds to stress in the workplace can be determined by the workplace environment. The Department of Homeland Security (DHS) has raised concerns that long-term exposures to stressors may reduce individual resilience and negatively affect employee’s physical and mental well-being. To explore DHS workforce resiliency, the IOM hosted two workshops in 2011 focused on DHS’s operational and law enforcement personnel and its policy and program personnel with top secret security clearances.
Released: April 05, 2012
In 1993, the National Research Council (NRC) released its report, Understanding Child Abuse and Neglect, which identified child maltreatment as a devastating social problem in America. The report noted that abuse and neglect were the cause of thousands of child deaths each year, and research in the field of child maltreatment was relatively undeveloped. Nearly 20 years later, child maltreatment research has greatly expanded, however, many critical gaps in knowledge remain. The IOM and NRC held a workshop to review the accomplishments of the past two decades of research related to child maltreatment, identify remaining gaps, and consider potential research priorities.
Released: April 04, 2012
Whether it’s suspect scallions from Mexico or contaminated ingredients from China used in the blood thinner heparin, the FDA is intimately familiar with the daunting task of policing the safety of food and medical products faced by regulators abroad. The FDA is responsible for protecting American consumers from unsafe food, medicines, biologics, and medical products that originate from many different countries and are transported through complex supply chains. The IOM formed a committee to identify the core elements of food, medicine, medical product, and biologics regulatory systems in developing countries; to pin-point the main gaps in these systems; and to design a strategy to leverage the expertise of the FDA and other stakeholders to strengthen regulatory systems abroad.
Released: April 03, 2012
Recent research suggests that obesity and excess weight can influence cancer survival and recurrence. Given the increasing rate of obesity and an aging population more susceptible to cancer, there is mounting concern about obesity’s role in fueling tumor growth. At an IOM workshop, experts presented the latest evidence on the obesity-cancer link and the possible mechanisms underlying that link, as well as potential interventions to mitigate the effects of obesity on cancer, and research and policy measures needed to counter the expected rise of cancer incidence and mortality due to an increasingly overweight and older population.
Released: April 02, 2012
A 2010 IOM report, Promoting Cardiovascular Health in the Developing World, found that not only is it possible to reduce the burden of cardiovascular disease and related chronic diseases in developing countries, but also that such a reduction will be critical to achieving global health and development goals. As part a series of follow-up activities to the 2010 report, the IOM held a workshop that aimed to identify what is needed to create tools for country-led planning of effective, efficient, and equitable provision of chronic disease control programs.
Released: March 30, 2012
Although epilepsy is one of the nation’s most common neurological disorders, public understanding of it is limited. Living with epilepsy is about much more than just seizures; the disorder is often defined in practical terms, such as challenges in school, uncertainties about social situations and employment, limitations on driving, and questions about independent living. The IOM examines the public health dimensions of the epilepsies, focusing on public health surveillance and data collection; population and public health research; health policy, health care, and human services; and education for people with the disorder and their families, health care providers, and the public.